A Food and Drug Administration advisory panel voted Thursday to recommend relaxing current restrictions on BPC-157, a synthetic peptide that has surged in popularity through social media wellness communities and among athletes seeking recovery benefits. The committee's recommendation marks a significant step in the regulatory review of a compound that has largely existed in a legal gray area.

BPC-157, short for Body Protection Compound-157, has been promoted online for purported benefits including accelerated tissue healing, reduced inflammation, and improved gut health. Despite widespread use, the peptide has not been approved by the FDA for any medical indication, and until now it has faced restrictions that limited its availability through compounding pharmacies.

The advisory panel's two-day meeting included testimony from scientists, clinicians, and public commenters. Members weighed existing preclinical and limited human study data before casting their votes in favor of easing access. Supporters argued the compound's safety profile and public demand warranted a more permissive regulatory posture, while some scientists urged caution given the relative lack of large-scale clinical trials in humans.

The vote does not constitute FDA approval of BPC-157, nor does it authorize any specific medical claims. Rather, it advises the agency on how strictly the peptide should be regulated under current frameworks governing compounded medications. A formal FDA decision is expected to follow the panel's recommendation after agency review.

The broader context of the panel meeting included discussion of peptide compounds more generally, reflecting growing regulatory attention to a category of substances that has outpaced formal scientific review. Consumer interest in peptides has accelerated significantly in recent years, fueled in part by high-profile endorsements from fitness influencers and podcasters.